Sweden
· Delayed Price · Currency is SEK Enorama Pharma AB Statistics
Total Valuation
Enorama Pharma AB has a market cap or net worth of SEK 247.34 million. The enterprise value is 238.05 million.
| Market Cap | 247.34M |
| Enterprise Value | 238.05M |
Important Dates
The last earnings date was Friday, November 15, 2024.
| Earnings Date | Nov 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Enorama Pharma AB has 60.47 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 60.47M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.57% |
| Owned by Institutions (%) | 1.78% |
| Float | 22.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.70 |
| EV / Sales | 17.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.90, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.90 |
| Quick Ratio | 1.62 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.10 |
Financial Efficiency
Return on equity (ROE) is -133.12% and return on invested capital (ROIC) is -73.12%.
| Return on Equity (ROE) | -133.12% |
| Return on Assets (ROA) | -50.29% |
| Return on Capital (ROIC) | -73.12% |
| Revenue Per Employee | 2.65M |
| Profits Per Employee | -7.11M |
| Employee Count | 5 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 1.38 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +62.95% in the last 52 weeks. The beta is 1.43, so Enorama Pharma AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.43 |
| 52-Week Price Change | +62.95% |
| 50-Day Moving Average | 4.22 |
| 200-Day Moving Average | 4.09 |
| Relative Strength Index (RSI) | 44.29 |
| Average Volume (20 Days) | 12,277 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Enorama Pharma AB had revenue of SEK 13.26 million and -35.55 million in losses.
| Revenue | 13.26M |
| Gross Profit | 3.19M |
| Operating Income | -31.71M |
| Pretax Income | -35.55M |
| Net Income | -35.55M |
| EBITDA | -31.18M |
| EBIT | -31.71M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 9.62 million in cash and 333,000 in debt, giving a net cash position of 9.28 million or 0.15 per share.
| Cash & Cash Equivalents | 9.62M |
| Total Debt | 333,000 |
| Net Cash | 9.28M |
| Net Cash Per Share | 0.15 |
| Equity (Book Value) | 33.72M |
| Book Value Per Share | n/a |
| Working Capital | 14.90M |
Cash Flow
| Operating Cash Flow | -46.56M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 24.03%, with operating and profit margins of -239.11% and -268.08%.
| Gross Margin | 24.03% |
| Operating Margin | -239.11% |
| Pretax Margin | -268.08% |
| Profit Margin | -268.08% |
| EBITDA Margin | -235.13% |
| EBIT Margin | -239.11% |
| FCF Margin | n/a |
Dividends & Yields
Enorama Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |